November 16, 2018 06:57 AM ESTUpdated 09:23 AM
Financing
Startups

With ra­dio­ther­a­py en vogue, Bel­gian start­up nabs near­ly $42M in Se­ries A fund­ing

ENDPOINTS

In­ter­est in tar­get­ed ra­di­a­tion treat­ments was buoyed last month with No­var­tis’ $NVS $2.1 bil­lion bet on En­do­cyte that put the spot­light on a decades …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times